ABSTRACT
INTRODUCTION
Abnormalities of the fetal urinary tract are among the most frequent anomalies diagnosed at prenatal ultrasound screening and, among them, obstructive uropathy has a prevalence of 3 per 10 000 births 1 . Renal function can be compromised when the obstruction is subvesical or affects both kidneys. Potential hyperpressure within the urinary tract leads to kidney damage and consequently to renal failure postnatally 2, 3 .
Prenatal management relies on several methods to predict postnatal renal outcome. Amniotic fluid volume reflects fetal diuresis. Severe oligohydramnios is considered to be an indicator of poor prognosis, although the presence of normal amniotic fluid volume does not guarantee normal postnatal renal function [4] [5] [6] . Use of biochemical markers has been proposed, of which fetal serum β2-microglobulin has been found to predict postnatal renal function in obstructive uropathy [7] [8] [9] [10] . However, controversial results have been observed and fetuses with normal prenatal fetal serum β2-microglobulin and poor kidney function after birth have been described 5 . These studies included only a single fetal serum β2-microglobulin assay. We hypothesize that a change in fetal serum β2-microglobulin levels occurs during pregnancy in cases of bilateral or low obstructive uropathy, reflecting possible worsening of renal injury. In this study, we investigated whether a second fetal serum β2-microglobulin assay would improve prediction of postnatal renal function.
SUBJECTS AND METHODS
We retrospectively studied postnatal renal function in patients who presented prenatally with bilateral or low obstructive uropathy and for whom fetal blood was sampled at least twice during pregnancy in order to assay fetal serum β2-microglobulin. Between 2000 and 2012, fetal blood samples were sent from different institutions to our laboratory for biochemical analysis. Amniotic fluid volume at the time of each sampling was recorded. Oligohydramnios was defined by an amniotic fluid index (sum of the vertical diameter of the largest amniotic fluid pocket in each of the four quadrants of the uterus) of < 5 cm 11 . Fetuses that underwent vesicoamniotic shunting or fetal cystoscopy were excluded. Fetal blood was sampled in utero with a 20-gauge needle at 20-38 weeks' gestation. Between two and four blood samples were drawn from each fetus. Repetition of fetal blood sampling was part of the routine diagnostic work-up, which was determined by the physician at the institution in charge of the patient's care. The physician in charge chose to repeat fetal blood sampling to confirm the first result, or when there was a subsequent worrying decline in amniotic fluid volume or abnormal appearance of the renal parenchyma on ultrasound. The interval between the first and last fetal blood sampling was at least 7 days. Only the first and last samples were taken into account for the final analysis. In accordance with French law, consent for fetal blood sampling, karyotyping, laboratory testing and pathological examination was obtained from the parents.
β2-microglobulin was assayed in fetal serum (immunoturbidimetry, AU 400, Beckman Coulter, Fullerton, CA, USA). The β2-microglobulin threshold used to distinguish favorable from adverse renal outcome was 5 mg/L, as described previously by Dommergues et al. 10 . Using 116 normal control samples, we established a reference curve of fetal serum β2-microglobulin according to gestational age. These patients underwent fetal blood sampling at 19-38 weeks' gestation, at the time of termination of pregnancy (TOP) for a variety of indications: genetic disease, cerebral malformation, fetal toxoplasmosis or limb malformations (excluding uropathy or nephropathy, oligohydramnios and cardiac malformations).
Pregnancy outcome and final urological diagnosis were documented in all cases. In accordance with French law, TOP was possible at parental request in cases of poor renal prognosis indicated by abnormal appearance of the renal parenchyma on ultrasound and/or severe oligohydramnios and/or abnormal β2-microglobulin results. The final diagnosis was based on either the results of postnatal evaluation (surgical, clinical and imaging findings) for liveborn infants or fetal autopsy for cases of TOP and intrauterine fetal death (IUFD). In cases of TOP or IUFD, a detailed histological examination of the kidneys was performed at autopsy. Histological kidney lesions were defined by the presence of dysplasia, characterized by renal medullary fibrosis, microcysts, nephron reduction and the presence of primitive ducts. For liveborn infants, renal function was assessed based on serum creatinine levels and glomerular filtration rate, calculated using the Schwartz formula 12 , and was evaluated after a minimum follow-up of 2 years for surviving children (median, 4 (range, 2-12) years). Renal failure was defined by a glomerular filtration rate of < 59 mL/min/1.73 m 2 (NKF KDOQI classification) 13 or, if glomerular filtration rate was unknown, by serum creatinine > 60 μmol/L 14 . We classified renal outcome as favorable or adverse: favorable when postnatal renal function was normal and adverse when postnatal chronic renal failure or renal histological lesions at autopsy were present 15 . The inclusion of TOP and histological renal lesions in our results led us to express them as a composite renal outcome measure instead of renal function. For each patient, accuracy in the prediction of poor renal outcome was studied for both the first and last measurement of β2-microglobulin in fetal serum. We also studied the accuracy of the first and last amniotic fluid volume evaluated at the time of fetal blood sampling.
Statistical analysis
Chi-square test and Fisher's exact test were used for comparisons of percentages. P < 0.05 was considered statistically significant. Statistical analyses were performed using R software, version 2.0.0 (www.r-project.org, Foundation for Statistical Computing, Vienna, Austria). This study was exempt from ethical review board approval because of its retrospective nature and because, at the time of prenatal diagnosis, fetal serum β2-microglobulin assessment was part of the routine diagnostic work-up.
RESULTS
During the study period, 42 patients with a fetus with bilateral or low urinary tract obstruction underwent sequential fetal blood sampling for β2-microglobulin assay. Table 1 summarizes the final urological diagnosis and pregnancy outcome. Median gestational age at diagnosis was 23 (interquartile range (IQR), [22] [23] [24] [25] weeks. All fetuses had normal karyotype and there were no syndromic associations. There were 21 TOPs, one IUFD and 20 liveborn infants. Six fetuses (all TOPs) presented pulmonary hypoplasia on pathological examination. Among the liveborn infants, no impaired pulmonary function was noted. Renal dysplasia was noted on histological examination in the 21 cases of TOP and the case of IUFD. Among the 20 liveborn infants, six developed renal failure, of which one died within the first Of the 42 cases, serial fetal blood samples for β2-microglobulin assay were obtained on two, three and four occasions in 31, nine and two cases, respectively. For the purposes of this study, we took into account only the first and last fetal serum β2-microglobulin measurements, obtained at a median of 24 + 6 (IQR, 23 + 2 to 30 + 3) and 32 (IQR, 29 + 6 to 33 + 6) weeks' gestation, respectively. The median interval between the first and last fetal serum sampling was 31 (IQR, 18-49) days. Table 2 describes postnatal renal outcome in the 42 cases of obstructive uropathy according to the change in fetal serum β2-microglobulin level between the first and last measurement. In 30 (71.4%) cases, the first and last measurements were concordant. Of these, the prediction of postnatal renal function according to a fetal serum β2-microglobulin threshold of 5 mg/L was accurate in 28 cases, but incorrect in two. In 12 (28.6%) cases, levels of fetal serum β2-microglobulin at first and last measurements differed. Prediction of postnatal renal function based on the last β2-microglobulin measurement was correct in 11 of these cases. Figure 1 shows the improved prediction of renal outcome when using the last β2-microglobulin measurement. Figure 2 shows the change in β2-microglobulin levels between first and last fetal blood sampling in cases with adverse and favorable renal outcome, according to gestational age at sampling. The reference curve of fetal β2-microglobulin levels according to gestational age derived from the controls with normal renal function is shown in Figure 3 . In the absence of uropathy, there was no increase in fetal serum β2-microglobulin as pregnancy progressed. Table 3 describes the postnatal renal function in the 42 cases with obstructive uropathy according to the change in amniotic fluid volume. In 30 (71.4%) cases, the first and last assessments of amniotic fluid volume were consistent. The prediction of postnatal renal function according to an amniotic fluid index cut-off of 5 cm correlated with the true outcome in 19 of these cases but did not correlate with the true outcome in 11. In 12 (28.6%) cases in which amniotic fluid volume at the first and last Table 2 Change in fetal serum β2-microglobulin concentration (β2m) between first and last fetal blood sampling, according to postnatal renal outcome in 42 cases of prenatally diagnosed obstructive uropathy, using a β2m cut-off of 5 mg/L to predict renal outcome assessments differed, the last assessment predicted renal outcome correctly in 11 cases. Accuracy of the changes in β2-microglobulin concentration in fetal serum and amniotic fluid volume between the first and last assessment in the prediction of renal outcome is shown in Table 4 . Sensitivity of β2-microglobulin was significantly better for the last sample (96.4% vs 64.3%, Data are given as n (%). P = 0.005), with similar specificity for both measurements (85.7% vs 78.6%, non-significant). The sensitivity of amniotic fluid volume was also significantly better for the last assessment (75.0% vs 35.7%, P = 0.005), with similar specificity for both assessments (64.3% vs 71.4%, non-significant). There was no statistical Data are given as n/N (%).
relationship between the underlying etiology and diagnostic value of each test.
DISCUSSION
Bilateral and low urinary tract obstructions are a leading cause of renal failure in children and are the reason for over half of all pediatric renal transplantations [16] [17] [18] . However, predicting postnatal renal function is a challenge in fetal medicine. β2-microglobulin concentration in fetal serum has been shown to be a predictor of renal function in cases of obstructive uropathy, with variable diagnostic value 5, [7] [8] [9] [10] . Because these studies involved evaluation of a single assay at a given gestational age, little is known about a possible change in β2-microglobulin concentration in fetal serum during pregnancy or the assay timing that best predicts postnatal renal function. We hypothesized that sampling too early in pregnancy may at least partly explain a lack of sensitivity.
Our study examined the value of sequential fetal serum β2-microglobulin assays in bilateral or low obstructive uropathy for the prediction of postnatal renal function. Our results show that serial β2-microglobulin assay is more accurate than is a single assay in predicting renal outcome. Moreover, we observed that fetal serum β2-microglobulin is more accurate for predicting renal outcome than is amniotic fluid volume assessment.
In our study, serial values of β2-microglobulin in fetal serum were usually either stable or increased. We hypothesized that this increase occurs because renal injury worsens with increasing duration of the urinary tract obstruction. The trend observed in the reference curve consolidates this hypothesis. Worsening of renal lesions is a pathophysiological theory that justifies the potential benefit of vesicoamniotic shunting or in-utero fetal cystoscopy in the case of fetal obstructive uropathy. Indeed, fetal therapy could prevent renal damage by reducing excess pressure in the upper urinary tract 2, 19, 20 . The other reason that justifies in-utero therapy is restoration of amniotic fluid volume to prevent pulmonary hypoplasia 21 . Although fetal therapy seems to improve survival by reducing the risk of pulmonary hypoplasia, its role in improving renal function is unclear 21 . One of the secondary objectives of the PLUTO trial was to determine the long-term effect of shunting, particularly on renal function 22 . Unfortunately, the study was stopped before the planned end of recruitment because of the low number of inclusions, and therefore the question has not been answered fully 23 . Currently, there is one experimental study on fetal lambs that shows worsening kidney damage with increasing duration of urinary tract obstruction 24 . Kitagawa et al. ligated the urethra of male fetal lambs at 60 days' gestation and they were delivered 20-31 days later 24 . The group that were delivered 20 days after urethral ligature had better preservation of the nephrogenic zone than did the group that were delivered 31 days after the operation. Our study is in line with these findings because it shows that fetal serum β2-microglobulin, which is used as a marker of postnatal renal function, may change during the course of pregnancy. Moreover, a recent study demonstrated that a high level of fetal serum β2-microglobulin is associated with renal histological injury 25 . Our results show that, the later in pregnancy that fetal serum β2-microglobulin is assayed, the greater the accuracy of the prediction of postnatal renal function. Given the risk to the fetus from fetal blood sampling, it would be ideal to take only a single sample, therefore these results raise the question of the best time to sample fetal serum β2-microglobulin. The optimal timing of fetal serum β2-microglobulin assay remains a matter of debate, but probably depends on the severity of the obstruction. Fetal serum β2-microglobulin assay performed later in pregnancy would reduce the false-negative rate (sensitivity increased from 64.3% to 96.4% between first and last measurements), and β2-microglobulin concentration measured close to delivery probably best reflects postnatal function. However, late sampling would delay diagnosis of the earliest forms of severe renal damage, which would be associated with increased fetal serum β2-microglobulin earlier in pregnancy. However, these forms would be accompanied by other signs of severity, such as severe oligohydramnios and hyperechogenic kidneys.
Using a 5-mg/L cut-off of fetal serum β2-microglobulin for predicting renal outcome, Dommergues et al. observed 67% sensitivity and 100% specificity in the prediction of poor renal outcome in their study of 61 cases of uropathy 10 . Using the same 5-mg/mL cut-off, we found similar sensitivity (64.3%) and good specificity (78.6%) based on the first sample, and sensitivity increased to 96.4% when the last β2-microglobulin measurement was taken into account. This finding justifies a second fetal blood sampling, especially when the first β2-microglobulin value is normal or borderline, or when there is a worrying decline in the amniotic fluid volume or the ultrasound appearance of the renal parenchyma is abnormal.
It should be noted that, in 16 cases, repeat fetal blood sampling was performed despite normal amniotic fluid volume (Table 3 ). This decision was made by the physician in charge either because the biochemical result of the first fetal sample was borderline or discordant with the amount of amniotic fluid observed, or because they considered the first sample to have been obtained too early. A possible selection bias in our study is due to the retrospective design and the fact that the decision to repeat sampling depended on the center that the patient was attending. Another limitation of our study is the proportion of TOPs, and thus it may be argued that renal function is difficult to assess. However, at histological examination, areas of renal dysplasia were large in all TOP cases, making it unlikely that these cases would have had normal postnatal renal function.
In conclusion, in bilateral or low obstructive uropathy, sequential fetal serum β2-microglobulin assay reliably predicted postnatal renal function with significantly better sensitivity than that of a single assay. This may be due to worsening of renal injury as the duration of urinary tract obstruction increases.
